SwabSeq still has steps to take before it can make their agnostic test available to the public. In addition to developing the new technology, it also must obtain regulatory approval from the Food and ...

FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...

Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc. today announced it has been awarded a contract from the Division of Research, Innovation, and Ventures (DRIVe), under the Biomedical Advanced ...

Chemo-praidict eBC: A deep learning solution for predicting pathological complete response on biopsies of breast cancer patients treated with neoadjuvant chemotherapy. Big data analysis of outcomes in ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...